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BACKGROUND
Controlled oxygen therapy was developed and used to minimize respiratory problems in people with lung disease for many years. The standard oxygen delivery method is compressed oxygen in gas bottles. In the last decade, commercial oxygen concentrators have been used to alleviate respiratory problems in people with lung disease. Since well-controlled studies of 0 2 concentrators has not been tested above 6000 feet, we evaluated one commercial device (Air Sep 0 2 Con) to determine the effectiveness of this device to deliver 4-5 LPM of 95% or greater oxygen at sea level and at several altitudes for up to 8 hours. The successful test of the 0 2 concentrator would reduce logistical support to ship and store 0 2 cylinders for high altitude operations.
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EXECUTIVE SUMMARY
Supplying medical oxygen at high altitude sites is a major logistical problem.
Oxygen concentrators based on molecular sieve technology provide an almost inexhaustible source of medical grade oxygen at a relatively low cost. However, data on the functional characteristics of 0 2 concentrators at high altitudes are minimal.
Our objective was to determine the effectiveness of the oxygen concentrator at moderate and high altitudes. The study measured the maximum sustained 0 2 flow rate, The objective of this study was to measure the maximum flow rate sustainable for 8 hours at SL, at moderate to very high altitudes (2,000-18,000 ft, in 2,000 ft increments). In addition, the outflow gas [0 2 ], flow rate and internal temperature (Ti)
were measured to assess gas quality and quantity for breathing.
METHODS
DESIGN AND EXPERIMENTAL PROCEDURES
The effectiveness of the 0 2 concentrator (AirSep, Model Newlife, Figure 1 Generally, all variables were stable over the duration of the tests. However, temperature increased slightly and steadily (~4°C rise) over the first 2 hours before stabilizing.
RESULTS AND DISCUSSION
The mean ±SD for SL through 18,000' intervals for the three measured variables (flow-LPM, oxygen-%, and temperature °C) over each 8 hour test period are given in Table 1 . The flow-rate averaged 4.5 LPM ± 0.2 LPM for baseline (SL) through 18,000';
[0 2 ] averaged 95.3% ± 0.2% for baseline (SL) through 18,000' (Table 1) , and the average T, (°C) was 51.9°C ± 3.6°C for baseline (SL) through 18,000'. 
CONCLUSIONS
From sea level to 18,000' the 0 2 concentrator provided medical grade (95% 0 2 or greater) at a maximal flow rate of about 4.5 LPM. Under these operating conditions the concentrator was capable of sustaining this level of oxygen delivery for at least 8 hours.
It is recommended that the 0 2 concentrator provided the bulk of the medical oxygen requirements for studies conducted at Pikes Peak Laboratory. The bottled 0 2 tanks should be used only when electrical power is interrupted during these operations. 
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